L. Endahl

发表

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

B. Zinman, J. Rosenstock, C. Mathieu, 2011, The Lancet.

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial

L. Niskanen, Lawrence A Leiter, A. Vaag, 2012, European journal of endocrinology.

A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine

J. DeVries, P. Home, K. Birkeland, 2011 .

Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data

A. Astrup, T. Wadden, M. Lean, 2021, International Journal of Obesity.

Increasing inequality in ischaemic heart disease morbidity among employed men in Denmark 1981-1993: the need for a new preventive policy.

F. Tüchsen, L. Endahl, F. Tüchsen, 1999, International journal of epidemiology.

Developing, Planning and Conducting an Interim Analysis: Lessons From the DEVOTE Cardiovascular Outcomes Trial (Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events)

A. Moses, I. C. Helmark, A. Hvelplund, 2019, Therapeutic innovation & regulatory science.

Glucagon/GLP-1 receptor co-agonist NNC9204-1177 reduced body weight in adults with overweight or obesity but was associated with safety issues

S. Toubro, M. Friedrichsen, R. Goldwater, 2022, medRxiv.

A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

J. Plank, T. Pieber, C. Magnes, 2005, Diabetes care.

N. Fallentin, B. Juul-Kristensen, P. Frost, 2020 .

Time‐action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups *

L. Heinemann, T. Heise, H. Haahr, 2006, Diabetes, obesity & metabolism.

Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double‐blind, controlled trial *

O. Kordonouri, T. Danne, M. Fjording, 2008, Pediatric diabetes.

Albumin‐bound basal insulin analogues (insulin detemir and NN344): comparable time‐action profiles but less variability than insulin glargine in type 2 diabetes

T. Heise, L. Nosek, O. Klein, 2007, Diabetes, obesity & metabolism.

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.

L. Heinemann, T. Heise, C. Kapitza, 2004, Diabetes.

Prevalence proportion ratios: estimation and hypothesis testing.

M R Petersen, J Deddens, T. Skov, 1998, International journal of epidemiology.

Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes

B. Zinman, H. Rodbard, C. Mathieu, 2012, Diabetes Care.

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

S. Gough, B. Zinman, C. Mathieu, 2012, Diabetes, obesity & metabolism.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

J. Rosenstock, A. King, A. Garber, 2012, The Lancet.

PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALS.

B. Bode, A. King, D. Einhorn, 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis.

P. Gøtzsche, P. Halberg, L. Rydgren, 1996, Scandinavian journal of rheumatology.

[Evaluation of surgical interventions in Denmark].

B. Ottesen, H. Kehlet, T. Schroeder, 2001, Ugeskrift for laeger.

Insulin Degludec in Type 1 Diabetes

J. DeVries, P. Home, K. Birkeland, 2011, Diabetes Care.

Superior glycaemic control with once‐daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial

Y. Onishi, R. Rabøl, L. Endahl, 2013, Diabetes, obesity & metabolism.

A 1-year, randomized, treat-to-target trial (BEGIN Once Long)

B. Zinman, H. Rodbard, C. Mathieu, 2012 .

Physical exposure assessment in monotonous repetitive work--the PRIM study.

J P Bonde, N. Fallentin, B. Juul-Kristensen, 2001, Scandinavian journal of work, environment & health.

Insulin detemir under steady‐state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes

T. Heise, C. Kapitza, E. Draeger, 2006, Diabetic medicine : a journal of the British Diabetic Association.

Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial

T. Wadden, P. Auerbach, D. Rubino, 2020, Obesity Facts.

Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co‐formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial

H. Rodbard, T. Pieber, J. Zacho, 2016, Diabetes, obesity & metabolism.

Efficacy and safety of once‐daily insulin degludec/insulin aspart compared with once‐daily insulin glargine in participants with Type 2 diabetes: a randomized, treat‐to‐target study

B. Bode, H. Jang, T. V. Skjøth, 2016, Diabetic medicine : a journal of the British Diabetic Association.

Insulin degludec, a new generation ultra-long acting insulin, used once daily or 3-times weekly in people with type 2 diabetes: comparison to insulin glargine

B. Zinman, J. Rosenstock, C. Mathieu, 2010 .